This inventor holds 2 USPTO granted patents. Top assignees: Jcr Pharmaceuticals Co., Ltd., New York Blood Center, Inc., Santen Pharmaceutical Co., Ltd.. Active years: 1994-1996.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:



Years Active: 1994-1996
Title: The Innovations of Toyohiko Nishimura
Introduction
Toyohiko Nishimura is a notable inventor based in Hyogo, Japan. He has made significant contributions to the field of ophthalmology through his innovative patents. With a total of 2 patents, Nishimura's work focuses on developing solutions that enhance the treatment of ophthalmic wounds.
Latest Patents
Nishimura's latest patents include a fibronectin-containing ophthalmic solution and a method of preserving it. This stable and soluble multi-dose ophthalmic solution contains fibronectin, an amino acid, a sugar, and a lower alkyl p-hydroxybenzoate. The patent also discloses a method for treating ophthalmic wounds using this solution, along with a process for preparing fibronectin for ophthalmic use. Additionally, it includes a method for lyophilizing an aqueous solution of fibronectin free of albumin, a method for inhibiting bacterial growth in the ophthalmic solution while preserving the cellular adhesion and wound healing activities of fibronectin, and a method for administering a wound-healing accelerator solution.
Career Highlights
Throughout his career, Nishimura has worked with reputable organizations such as the New York Blood Center and JCR Pharmaceuticals Co., Ltd. His experience in these institutions has contributed to his expertise in developing innovative solutions for ophthalmic care.
Collaborations
Nishimura has collaborated with notable individuals in his field, including Bernard Horowitz and Richard W. Shulman. These collaborations have likely enriched his research and development efforts.
Conclusion
Toyohiko Nishimura's contributions to ophthalmology through his innovative patents demonstrate his commitment to improving patient care. His work continues to influence the field and offers promising solutions for treating ophthalmic wounds.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile